ClinicalTrials.gg
CompletedNCT06831344Updated Dec 19, 2025Results posted

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

A Phase 1 interventional study of Vonoprazan ODT-1 or ODT-2 without Water and Vonoprazan ODT-1 or ODT-2 with Water in Healthy Volunteers, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Erosive Esophagitis
  • Non-erosive Gastroesophageal Reflux Disease
  • Vonoprazan
03

In context

Lead sponsor

Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is 18 to 55 years of age, inclusive, at Screening.
  • The participant has a (BMI) 18 to 32 kg/m2, inclusive, at Screening.
  • The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead (ECG) results, and physical examination findings at Screening.
  • Female participants of must use an acceptable method of (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from signing the form (ICF) until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy or bilateral oophorectomy) or (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level >40 IU/mL during Screening).
  • Female participants must have a negative pregnancy test at Screening and upon Check-in.
  • The participant agrees to comply with all protocol requirements.
  • The participant is able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • The participant has a positive test result for surface antigen, virus antibody, or types 1 or 2 antibodies at Screening.
  • The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in.
  • The participant has a history of a neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the subject to participate.
  • The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (eg, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis (EE)), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
  • The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or results that preclude his/her participation in the study, as deemed by the investigator.
  • The participant has used any prescription (excluding hormonal ) and/or over-the-counter medications (including Cytochrome P450 3A4 () inducers) except acetaminophen (up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until the end of confinement on Study Day 23.
  • The participant has consumed grapefruit and/or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study.
  • The participant has consumed caffeine- or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug and/or is unable to abstain through the study.
  • The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  • The participant has a history of alcohol abuse and/or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects; 1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.
  • The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in.
  • The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
  • The participant has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  • The participant has a history of relevant drug and/or food allergies (ie, allergy to vonoprazan or or any significant food allergy that could preclude a standard diet in the clinical unit).
  • The participant has received a study drug in another study within 5-times the t1/2 of the study drug or 30 days of dosing, whichever is longer.
  • Female participants who are pregnant or lactating; intend to become pregnant before, during, or within 4 weeks after participating in this study; or intend to donate ova during this time period.
  • The participant is not suitable for entry into the study in the opinion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Sequence A, B, C, D, E: Vonoprazan 10 mg

    Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

    Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)

  • Experimental
    Sequence B, D, E, C, A: Vonoprazan 10 mg

    Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

    Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)

  • Experimental
    Sequence C, E, B, A, D: Vonoprazan 10 mg

    Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

    Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)

  • Experimental
    Sequence D, C, A, E, B: Vonoprazan 10 mg

    Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

    Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)

  • Experimental
    Sequence E, A, D, B, C: Vonoprazan 10 mg

    Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

    Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)

Interventions

  • DrugVonoprazan ODT-1 or ODT-2 without Water

    Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water

  • DrugVonoprazan ODT-1 or ODT-2 with Water

    Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe

  • Vonoprazan will be administered orally as a tablet

06

What researchers measure

Primary outcomes

  1. Maximum Observed Drug Concentration (Cmax) of Vonoprazan

    Cmax of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan

    AUC0-t of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  3. AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan

    AUC0-inf of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Secondary outcomes

  1. Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan

    Tmax of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  2. Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan

    Tlag of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  3. Terminal Elimination Rate Constant (λz) of Vonoprazan

    λz of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  4. Terminal Phase Half-life (t1/2) of Vonoprazan

    t1/2 of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  5. Apparent Oral Clearance (CL/F) of Vonoprazan

    CL/F of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

  6. Apparent Volume of Distribution (Vz/F) of Vonoprazan

    Vz/F of Vonoprazan was reported.

    Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

07

Results

Posted Dec 19, 2025

Participant flow

This study was conducted at single center in the United States from 14 February 2025 to 10 April 2025.

Participant flow — Overall Study
MilestoneVonoprazan 10 mg: Treatment Sequence 1Vonoprazan 10 mg: Treatment Sequence 2Vonoprazan 10 mg: Treatment Sequence 3Vonoprazan 10 mg: Treatment Sequence 4Vonoprazan 10 mg: Treatment Sequence 5
Started55555
Completed55555
Not completed00000

Outcome measures

PrimaryMaximum Observed Drug Concentration (Cmax) of Vonoprazan

Cmax of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Drug Concentration (Cmax) of Vonoprazan
nanogram per milliliter (ng/mL)Treatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Maximum Observed Drug Concentration (Cmax) of Vonoprazan6.11 ± 47.85.81 ± 41.45.46 ± 36.15.72 ± 46.25.40 ± 38.4
Statistical analysis
  • Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm percentage (%): 113.26 · 90% CI 104.86 to 122.33Geometric least square mean (GLSM) ratios were calculated by taking antilog of difference of least square means and associated 90% confidence intervals (CIs) from linear mixed effect model analyzing natural logarithms of corresponding PK parameters.
  • Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 107.65 · 90% CI 99.67 to 116.28GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 101.19 · 90% CI 93.68 to 109.30GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment D: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 105.94 · 90% CI 98.08 to 114.43GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment A: Vonoprazan 10 mg vs Treatment B: Vonoprazan 10 mg · Ratio of glsm (%): 95.05 · 90% CI 88.00 to 102.67GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment D: Vonoprazan 10 mg · Ratio of glsm (%): 104.69 · 90% CI 96.93 to 113.08GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan

AUC0-t of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
ng*hour/mLTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan57.1 ± 45.854.8 ± 42.052.8 ± 41.751.7 ± 47.649.8 ± 38.5
Statistical analysis
  • Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 114.62 · 90% CI 107.46 to 122.24GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 110.01 · 90% CI 103.14 to 117.33GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 106.00 · 90% CI 99.39 to 113.06GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment D: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 103.87 · 90% CI 97.39 to 110.78GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment A: Vonoprazan 10 mg vs Treatment B: Vonoprazan 10 mg · Ratio of glsm (%): 95.98 · 90% CI 89.99 to 102.37GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment D: Vonoprazan 10 mg · Ratio of glsm (%): 97.99 · 90% CI 91.87 to 104.51GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
PrimaryAUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan

AUC0-inf of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · ng*hour/mL
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
ng*hour/mLTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan59.2 ± 44.357.1 ± 39.455.3 ± 39.054.1 ± 44.951.9 ± 36.3
Statistical analysis
  • Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 114.01 · 90% CI 107.28 to 121.17GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 109.99 · 90% CI 103.49 to 116.90GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 106.55 · 90% CI 100.26 to 113.24GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment D: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg · Ratio of glsm (%): 104.31 · 90% CI 98.15 to 110.86GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment A: Vonoprazan 10 mg vs Treatment B: Vonoprazan 10 mg · Ratio of glsm (%): 96.47 · 90% CI 90.77 to 102.53GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
  • Treatment C: Vonoprazan 10 mg vs Treatment D: Vonoprazan 10 mg · Ratio of glsm (%): 97.90 · 90% CI 92.11 to 104.05GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters.
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan

Tmax of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
hoursTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan2.00 (1.50 to 6.00)2.00 (1.50 to 6.00)2.12 (1.50 to 4.08)2.00 (1.50 to 6.00)2.00 (1.00 to 6.00)
SecondaryTime Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan

Tlag of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Median · hours
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan
hoursTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan0.32 (0.25 to 1.02)0.25 (0.25 to 1.00)0.32 (0.25 to 1.00)0.25 (0.25 to 1.50)0.27 (0.25 to 1.50)
SecondaryTerminal Elimination Rate Constant (λz) of Vonoprazan

λz of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Mean · per hour
Terminal Elimination Rate Constant (λz) of Vonoprazan
per hourTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Terminal Elimination Rate Constant (λz) of Vonoprazan0.0948 ± 0.01750.0998 ± 0.01880.0955 ± 0.01670.0963 ± 0.01400.0975 ± 0.0185
SecondaryTerminal Phase Half-life (t1/2) of Vonoprazan

t1/2 of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Mean · hours
Terminal Phase Half-life (t1/2) of Vonoprazan
hoursTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Terminal Phase Half-life (t1/2) of Vonoprazan7.54 ± 1.367.20 ± 1.427.48 ± 1.387.36 ± 1.227.35 ± 1.36
SecondaryApparent Oral Clearance (CL/F) of Vonoprazan

CL/F of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Mean · litres/hour (L/h)
Apparent Oral Clearance (CL/F) of Vonoprazan
litres/hour (L/h)Treatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Apparent Oral Clearance (CL/F) of Vonoprazan184 ± 78.9188 ± 76.0193 ± 72.5202 ± 89.2205 ± 75.9
SecondaryApparent Volume of Distribution (Vz/F) of Vonoprazan

Vz/F of Vonoprazan was reported.

Time frame:
Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Reported as:
Mean · litres (L)
Apparent Volume of Distribution (Vz/F) of Vonoprazan
litres (L)Treatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
Apparent Volume of Distribution (Vz/F) of Vonoprazan1930 ± 7351880 ± 6222030 ± 6782070 ± 7622100 ± 668

Adverse events

Collected over Day 1 to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Vonoprazan 10 mg0/25 (0%)0/25 (0%)2/25 (8%)
Treatment B: Vonoprazan 10 mg0/25 (0%)0/25 (0%)0/25 (0%)
Treatment C: Vonoprazan 10 mg0/25 (0%)0/25 (0%)1/25 (4%)
Treatment D: Vonoprazan 10 mg0/25 (0%)0/25 (0%)1/25 (4%)
Treatment E: Vonoprazan 10 mg0/25 (0%)0/25 (0%)1/25 (4%)
Most frequent other events
Most frequent other events
EventTreatment A: Vonoprazan 10 mgTreatment B: Vonoprazan 10 mgTreatment C: Vonoprazan 10 mgTreatment D: Vonoprazan 10 mgTreatment E: Vonoprazan 10 mg
ConstipationGastrointestinal disorders1/250/251/250/250/25
NauseaGastrointestinal disorders0/250/250/250/251/25
VomitingGastrointestinal disorders0/250/250/250/251/25
DizzinessNervous system disorders1/250/250/250/250/25
Dry skinSkin and subcutaneous tissue disorders0/250/250/251/250/25
ErythemaSkin and subcutaneous tissue disorders0/250/250/251/250/25

Baseline characteristics

The safety population included all participants who receive at least 1 dose of study drug. As planned, baseline data was collected and reported as single arm for all 25 participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean37.2 ± 8.66
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female15
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino6
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American16
White9
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • 7551 Metro Center Dr Ste 200
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

Results were first posted in Dec 2025, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 18, 2025
StartActual
Feb 14, 2025
Primary completionActual
Apr 5, 2025
CompletionActual
Apr 10, 2025
Results first posted
Dec 19, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06831344
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Feb 14, 2025
Primary completion
Apr 5, 2025
Completion
Apr 10, 2025
Results posted
Dec 19, 2025
Last update
Dec 19, 2025

Study contacts

Medical Director
study director · Phathom Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion